Brokerages Set Oculis Holding AG (NASDAQ:OCS) Price Target at $38.33

Oculis Holding AG (NASDAQ:OCS) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $38.3333.

OCS has been the subject of a number of recent research reports. Guggenheim lowered their price objective on Oculis from $75.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, June 1st. HC Wainwright reiterated a “buy” rating on shares of Oculis in a research note on Thursday, June 11th. Needham & Company LLC reduced their price target on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, June 1st. JPMorgan Chase & Co. reduced their price target on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Finally, Robert W. Baird lowered their price target on shares of Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research report on Monday, June 1st.

Oculis Stock Performance

NASDAQ OCS traded down $0.07 during trading hours on Friday, reaching $13.63. The company’s stock had a trading volume of 201,538 shares, compared to its average volume of 491,565. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $19.19 and a 200 day simple moving average of $23.63. Oculis has a 52 week low of $10.52 and a 52 week high of $34.47. The stock has a market cap of $790.27 million, a PE ratio of -6.40 and a beta of 0.44.

Oculis (NASDAQ:OCS) last posted its earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The company had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. Equities research analysts predict that Oculis will post -2.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new stake in shares of Oculis during the fourth quarter valued at about $80,000. Geode Capital Management LLC raised its stake in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Finally, Koshinski Asset Management Inc. acquired a new stake in Oculis in the first quarter worth about $238,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.